Genmab A/S
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $3.72B | $3.12B | $2.39B |
| Cost of Revenue | $238.0M | $143.0M | $33.0M |
| Gross Profit | $3.48B | $2.98B | $2.36B |
| Gross Margin | 93.6% | 95.4% | 98.6% |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | — | — | — |
| Operating Income | $1.07B | $972.0M | $772.0M |
| Operating Margin | 28.6% | 31.1% | 32.3% |
| Interest Expense | — | — | — |
| Pretax Income | $1.20B | $1.33B | $817.0M |
| Income Tax Expense | $241.0M | $193.0M | $186.0M |
| Net Income | $963.0M | $1.13B | $631.0M |
| Net Margin | 25.9% | 36.3% | 26.4% |
| EPS (Basic) | $15.50 | $17.66 | $9.67 |
| EPS (Diluted) | $15.37 | $17.53 | $9.58 |
| Shares Outstanding (Basic) | — | — | — |
| Shares Outstanding (Diluted) | — | — | — |
| Dividends Per Share | — | — | — |